EMHTF: AI 评分 40/100 — AI 分析 (4月 2026)

Emerald Health Therapeutics, Inc. focuses on the production, distribution, and sale of recreational and medical cannabis in Canada. The company offers various cannabis products under brands like SYNC Wellness and Emerald, operating as a subsidiary of Skye Bioscience, Inc.

Key Facts: AI Score: 40/100 Sector: Healthcare

公司概况

概要：

Emerald Health Therapeutics, Inc. is a Canadian cannabis company involved in the production, distribution, and sale of recreational and medical cannabis products. Operating as a subsidiary of Skye Bioscience, Inc., Emerald Health offers a range of cannabis products, facing strong competition in the evolving Canadian cannabis market.

EMHTF是做什么的？

Emerald Health Therapeutics, Inc. was initially founded as T-Bird Pharma Inc. before rebranding in June 2015 to reflect its focus on the burgeoning cannabis industry. Headquartered in Vancouver, Canada, the company cultivates, processes, and distributes a variety of cannabis products, including dried cannabis strains, pre-rolled cannabis, oral sprays, nano emulsion shots, and cannabis oil products. These products are marketed under several brands, including SYNC Wellness, fuse, Emerald, and Souvenir. Emerald Health aims to cater to both the recreational and medical cannabis markets in Canada. However, as of November 10, 2022, Emerald Health Therapeutics operates as a subsidiary of Skye Bioscience, Inc., marking a significant shift in its corporate structure. The company's evolution reflects the dynamic nature of the cannabis industry, with Emerald Health adapting its strategy to navigate regulatory changes and evolving consumer preferences. Its product portfolio is designed to appeal to a broad spectrum of cannabis users, from those seeking traditional dried flower to those preferring more innovative consumption methods like oral sprays and nano emulsion shots.

EMHTF的投资论点是什么？

Investing in Emerald Health Therapeutics, Inc. (EMHTF) presents a high-risk, high-reward scenario. The company's negative profit margin of -411.9% and gross margin of -66.7% indicate significant financial challenges. EMHTF operates in the competitive Canadian cannabis market, where profitability has been elusive for many players. A potential growth catalyst lies in the expansion of its product lines and market reach within Canada. However, investors should closely monitor EMHTF's financial performance and its ability to achieve sustainable profitability. The company's status as a subsidiary of Skye Bioscience, Inc. adds another layer of complexity, as its strategic direction may be influenced by its parent company. Given the current financial metrics and competitive landscape, EMHTF requires a turnaround strategy to deliver value to investors.

EMHTF在哪个行业运营？

Emerald Health Therapeutics operates within the Canadian cannabis industry, which has experienced significant growth since legalization but also faces challenges such as oversupply, regulatory hurdles, and intense competition. The market includes both recreational and medical cannabis segments, with evolving consumer preferences for different product formats. Key competitors include other licensed producers who are vying for market share. Emerald Health's success depends on its ability to differentiate its products, manage costs effectively, and navigate the complex regulatory landscape. The Canadian cannabis market is projected to continue growing, driven by increasing consumer acceptance and the development of new products and distribution channels.

Drug Manufacturers - Specialty & Generic

Healthcare

EMHTF有哪些增长机遇？

Expansion of Product Lines: Emerald Health can expand its product offerings to include new and innovative cannabis products, such as edibles, concentrates, and topicals. The market for these products is growing rapidly, driven by consumer demand for alternative consumption methods. By introducing new products, Emerald Health can attract new customers and increase its market share. The timeline for this growth opportunity is immediate, as the company can begin developing and launching new products in the near term. Success depends on effective product development and marketing strategies.
Geographic Expansion within Canada: Emerald Health can expand its distribution network to reach new markets within Canada. This could involve partnering with retailers in provinces where the company currently has limited presence or establishing its own retail locations. Geographic expansion would allow Emerald Health to increase its sales volume and diversify its revenue streams. The timeline for this growth opportunity is medium-term, as it may take time to secure partnerships and establish new retail locations. Success depends on effective market research and strategic partnerships.
Focus on Medical Cannabis Market: Emerald Health can focus on the medical cannabis market, which offers higher margins and greater regulatory certainty compared to the recreational market. This could involve developing cannabis-based pharmaceuticals or partnering with healthcare providers to offer cannabis-based treatments. The medical cannabis market is growing rapidly, driven by increasing awareness of the therapeutic benefits of cannabis. The timeline for this growth opportunity is long-term, as it may take time to develop new pharmaceuticals and secure regulatory approvals. Success depends on scientific research and clinical trials.
Strategic Partnerships and Acquisitions: Emerald Health can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. This could involve partnering with other cannabis companies, technology companies, or healthcare providers. Strategic partnerships and acquisitions can provide access to new technologies, markets, and expertise. The timeline for this growth opportunity is ongoing, as the company can continuously explore potential partnerships and acquisitions. Success depends on effective due diligence and integration.
Development of Proprietary Cannabis Strains: Emerald Health can invest in research and development to develop proprietary cannabis strains with unique characteristics, such as higher potency, unique flavor profiles, or specific therapeutic benefits. Proprietary strains can provide a competitive advantage and allow the company to differentiate its products. The timeline for this growth opportunity is long-term, as it may take time to develop and stabilize new strains. Success depends on scientific expertise and effective breeding programs.

Negative Profit Margin: Emerald Health Therapeutics has a profit margin of -411.9%, indicating substantial losses.
Negative Gross Margin: The company's gross margin is -66.7%, reflecting challenges in cost management and pricing.
P/E Ratio: Emerald Health Therapeutics has a P/E ratio of -0.27, signaling that the company is currently unprofitable.
Subsidiary Status: Emerald Health Therapeutics operates as a subsidiary of Skye Bioscience, Inc. since November 10, 2022.
Beta: The company has a beta of 0.63, suggesting lower volatility compared to the overall market.

EMHTF提供哪些产品和服务？

Produces dried cannabis strains for recreational and medical use.
Manufactures pre-rolled cannabis products for convenient consumption.
Develops and sells oral sprays containing cannabis extracts.
Offers nano emulsion shots for rapid cannabis absorption.
Produces cannabis oil products for various applications.
Markets its products under the SYNC Wellness, fuse, Emerald, and Souvenir brands.
Distributes cannabis products through various channels in Canada.

EMHTF如何赚钱？

Cultivates and processes cannabis plants.
Manufactures a range of cannabis products.
Distributes and sells products through retail channels and partnerships.
Generates revenue from the sale of cannabis products to recreational and medical consumers.

Recreational cannabis consumers in Canada.
Medical cannabis patients with prescriptions.
Retail partners who sell Emerald Health's products.
Wholesale distributors of cannabis products.

Brand recognition through SYNC Wellness, fuse, Emerald, and Souvenir brands.
Established distribution network in the Canadian cannabis market.
Proprietary formulations for oral sprays and nano emulsion shots.
Access to a range of cannabis strains and product formats.

什么因素可能推动EMHTF股价上涨？

Upcoming: Potential regulatory changes in the Canadian cannabis market that could benefit licensed producers.
Ongoing: Expansion of product lines to include new and innovative cannabis products.
Ongoing: Geographic expansion within Canada to reach new markets.
Ongoing: Focus on the higher-margin medical cannabis market.
Ongoing: Strategic partnerships and acquisitions to expand capabilities.

EMHTF的主要风险是什么？

Ongoing: Oversupply and price compression in the Canadian cannabis market.
Ongoing: Changing regulations and consumer preferences.
Potential: Competition from illicit cannabis producers.
Ongoing: Potential for further financial losses due to negative profit and gross margins.
Potential: Dependence on the Canadian cannabis market.

EMHTF的核心优势是什么？

Diverse product portfolio including dried cannabis, pre-rolls, oral sprays, and oils.
Established brands such as SYNC Wellness and Emerald.
Distribution network within the Canadian cannabis market.
Subsidiary of Skye Bioscience, Inc., providing potential access to resources and expertise.

EMHTF的劣势是什么？

Negative profit and gross margins indicating financial struggles.
Dependence on the Canadian cannabis market.
Intense competition from other licensed producers.
Operating as a subsidiary may limit strategic autonomy.

EMHTF有哪些机遇？

Expansion into new product categories such as edibles and concentrates.
Geographic expansion within Canada.
Focus on the higher-margin medical cannabis market.
Strategic partnerships and acquisitions to expand capabilities.

EMHTF面临哪些威胁？

Oversupply and price compression in the Canadian cannabis market.
Changing regulations and consumer preferences.
Competition from illicit cannabis producers.
Potential for further financial losses.

EMHTF的竞争对手是谁？

BevCanna Enterprises Inc — Focuses on cannabis-infused beverages and wellness products. — (BNOEF)
Canopy Growth Corp — One of the largest cannabis companies in Canada with a wide range of products. — (CNPOF)
Flower One Holdings Inc — Cultivates and processes cannabis at scale in Nevada. — (FLWPF)
Rubicon Organics Inc — Specializes in organic cannabis cultivation and premium products. — (HBCNF)
Imunex Inc — Focuses on cannabis-based health and wellness products. — (IMUN)

Key Metrics

MoonshotScore: 40/100

Company Profile

Headquarters: Vancouver, CA
Employees: 110
Founded: 2015

AI Insight

AI analysis pending for EMHTF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Emerald Health Therapeutics, Inc. do?

Emerald Health Therapeutics, Inc. is a Canadian cannabis company involved in the production, distribution, and sale of recreational and medical cannabis products. The company offers a range of cannabis products, including dried cannabis strains, pre-rolled cannabis, oral sprays, nano emulsion shots, and cannabis oil products, marketed under brands like SYNC Wellness and Emerald. Emerald Health operates as a subsidiary of Skye Bioscience, Inc., focusing on serving the Canadian cannabis market through various distribution channels.

What do analysts say about EMHTF stock?

As of 2026-03-18, formal analyst ratings for Emerald Health Therapeutics (EMHTF) are limited, likely due to its OTC listing and financial performance. Key valuation metrics, such as the negative P/E ratio, reflect the company's current lack of profitability. Growth considerations revolve around its ability to expand product lines, increase market share within Canada, and capitalize on the medical cannabis market. Investors should conduct thorough due diligence and consider the risks associated with investing in a company with negative profit margins and limited analyst coverage.

What are the main risks for EMHTF?

The main risks for Emerald Health Therapeutics include the oversupply and price compression in the Canadian cannabis market, which can negatively impact revenue and profitability. Changing regulations and consumer preferences pose additional challenges. Competition from both licensed and illicit cannabis producers further intensifies the competitive landscape. The company's negative profit and gross margins raise concerns about its financial sustainability. Dependence on the Canadian market exposes it to regional economic and regulatory risks. As an OTC-listed company, EMHTF faces additional risks related to liquidity and transparency.